Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 22, 2015Osteoporosis InternationalOpen Access

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSocrates E. PapapoulosLeiden University Medical CenterKLKurt LippunerUniversity of BernCRChristian RouxDélégation Paris 5

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Papapoulos et al. (2015) studied this question.

synapsesocial.com/papers/6a03d5b78235fcdee82b2f94https://doi.org/10.1007/s00198-015-3234-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research2010 · 1,120 citations
  2. 2Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension2011 · 344 citations
  3. 3The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension2013 · 252 citations
  4. 4Effects of denosumab on bone turnover markers in postmenopausal osteoporosis2010 · 256 citations
  5. 5The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)2011 · 701 citations